GSK vs Sanofi

GSK (GSK), health care, and Sanofi (SNY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Sanofi is worth $115.1B on the stock market and GSK $99.3B: Sanofi is valued at 16% more. GSK trades at 17.3 times earnings and Sanofi at 23.9; operating margins in their latest fiscal years were 24.3% and 14.5%. Over the past year GSK's share price has moved +6.42% and Sanofi's -4.48%.

Key facts

GSK market value
$99.3B
Sanofi market value
$115.1B
GSK P/E
17.3
Sanofi P/E
23.9
GSK revenue
$43.4BFY to 2025-12-31
Sanofi revenue
$48.4BFY to 2025-12-31
Superinvestors holding both
4

Market values as of .

GSK vs Sanofi: every measure side by side
Measure GSK Sanofi
SectorHealth CareHealth Care
Country United Kingdom France
Fiscal year ends2025-12-312025-12-31
Size
Market cap$99.3Blower$115.1Bhigher
Revenue$43.4Blower$48.4Bhigher
Earnings$7.6Blower$8.7Bhigher
Employees66,841lower74,846higher
Total assets$81.1Blower$140.7Bhigher
Valuation
P/E17.3lower23.9higher
P/S2.3lower2.4higher
P/B——
Dividend yield——
Profitability
Operating margin24.3%higher14.5%lower
Balance sheet
Net assets$21.7Blower$79.2Bhigher
Total liabilities$59.9Blower$61.1Bhigher
Total debt$19.2Blower$20.8Bhigher
Cash on hand$4.5Blower$8.5Bhigher
Price change
Today-1.77%lower-0.92%higher
1 year+6.42%higher-4.48%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": GSK / Sanofi). Who owns GSK · Who owns SNY

Further comparisons

Learn

Questions and answers

Which is bigger, GSK or Sanofi?

By market value, Sanofi is the larger: $115.1B against $99.3B for GSK. By revenue in its latest fiscal year, Sanofi is the larger: $48.4B against $43.4B for GSK.

Which has the higher P/E ratio?

Sanofi: 23.9, against 17.3 for GSK. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

GSK: 24.3%, against 14.5% for Sanofi. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Sanofi: $20.8B, against $19.2B for GSK. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both GSK and Sanofi?

In their latest 13F filings, Dodge & Cox team, Charles Brandes (founder), Ken Fisher and Richard Pzena hold both.

Cite this page

Funkfolio, “GSK vs Sanofi”, data as of 17 November 2026. https://funkfolio.com/compare/gsk-vs-sny

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.